Laxogenin

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: muscle energy weight

Research Overview

Current research on laxogenin-related compounds spans two main areas: (1) plant physiology/agricultural applications of laxogenin C (LGC), a natural spirostanol described as a plant-hormone derivative with brassinosteroid-like growth regulation, and (2) anti-doping/toxicology-focused evaluation of 5α-hydroxy-laxogenin, a spirostane-type steroid found in some dietary supplements marketed for anabolic effects. The plant-focused work has used metabolomics (LC–MS/MS) and phenotypic assays in tomato to link LGC exposure to dose-dependent changes in germination and seedling growth, alongside shifts in specific metabolites and pathways. The supplement/athlete-focused work has emphasized mechanistic androgen receptor (AR) assays in vitro and follow-up in vivo testing in a standard rodent model relevant to androgenic/anabolic activity.

The strongest evidence supports a plant growth–regulatory effect of LGC in tomato, with convergent metabolomic and phenotypic observations implicating phenylalanine metabolism and phenylpropanoid biosynthesis, including changes in l-phenylalanine, 2-hydroxycinnamic acid, and lignification-related phenylpropanoids (e.g., trans-ferulic acid). For 5α-hydroxy-laxogenin, the best-supported conclusion is that it can interact with the androgen receptor in vitro: it trans-activates AR in human prostate cells in a dose-dependent manner with a biphasic profile (antagonistic at lower concentrations and agonistic at higher concentrations), while showing no activity in a yeast androgen screen. However, in vivo evidence in orchiectomized rats treated for two weeks does not support androgenic or anabolic effects on classical androgen target tissues or muscle; at the highest dose tested, some tissues exhibited greater atrophy, arguing against a straightforward anabolic/androgenic phenotype under those conditions.

Key gaps remain. For LGC, broader validation across plant species, developmental stages, and agronomic conditions is needed, along with mechanistic studies that connect metabolite shifts to causal signaling targets and longer-term outcomes (e.g., yield, stress tolerance, and safety/ecotoxicology for agrichemical development). For 5α-hydroxy-laxogenin, further work should clarify pharmacokinetics, metabolism, and tissue exposure (to reconcile in vitro AR activity with in vivo null effects), evaluate longer dosing durations and additional endpoints, and assess safety/toxicity. Given its presence in supplements and potential relevance to doping control, additional research is also warranted on prevalence in products, analytical detection, and the biological significance of its biphasic AR modulation.

1. What conditions has Laxogenin been studied for?

  • Plant growth regulation (agriculture): Laxogenin C (LGC), described as a natural spirostanol derived from a plant hormone, was studied for effects on tomato seed germination, seedling growth, and seedling lignification (lignin-related development).

  • “Anabolic/androgenic” performance-enhancement claims (dietary supplements / doping context): A related compound, 5α-hydroxy-laxogenin (noted as synthetic and present in supplements), was studied for androgen receptor (AR) activity in vitro and for androgenic/anabolic effects in vivo in orchiectomized (castrated) rats.

2. Does it work in treating those conditions? Summarize the evidence.

  • Plant growth: In tomato, LGC showed a dose-dependent promoting effect on seed germination and seedling growth. Metabolomics (LC-MS/MS) identified differential metabolites and implicated changes in phenylalanine metabolism and phenylpropanoid biosynthesis, with phenotypic verification that LGC affected seedling lignification and levels of trans-ferulic acid and L-phenylalanine. This supports biological activity in plants, but it is not “treatment” of a disease—rather, growth regulation.

  • Androgenic/anabolic effects (humans/athletes): For 5α-hydroxy-laxogenin, evidence is mixed and overall does not support anabolic/androgenic efficacy in vivo:

    • In vitro: No activity in a yeast androgen screen, but it trans-activated the androgen receptor in human prostate cells in a dose-dependent manner, with a biphasic response (antagonistic at lower concentrations, agonistic at higher concentrations).

    • In vivo (rat model): In orchiectomized rats treated for 2 weeks at three dosages, there were no increases in weights of androgen target tissues (prostate, seminal vesicle, penis) or anabolic target tissues (levator ani, hindlimb skeletal muscles). At the highest dose (36 mg/kg body weight), some tissues showed significantly higher atrophy.

Overall: LGC appears effective as a plant growth regulator in the tomato model. For supplement-style “anabolic” use, the studied synthetic analog shows receptor activity in vitro but no anabolic/androgenic benefit in a castrated-rat model over 2 weeks.

3. What health benefits does it have?

  • Human health benefits: The provided abstracts do not demonstrate any clinical health benefits in humans. The supplement-related studies focus on androgen receptor activity and doping/safety questions rather than therapeutic outcomes.

  • Performance/anabolic benefits: The in vivo rat study found no anabolic effects on muscle weights and no androgenic effects on androgen-responsive tissues, which argues against marketed anabolic benefits (at least under the tested conditions).

  • Agricultural/plant benefits (not human health): LGC promoted tomato germination and seedling growth and altered pathways tied to growth and lignification (phenylalanine/phenylpropanoid pathways).

4. Does it have any downsides or side effects?

  • Potential androgen receptor–mediated risks (theoretical/early evidence): 5α-hydroxy-laxogenin can activate the androgen receptor in human prostate cells at higher concentrations, suggesting a plausible mechanism for androgen-like effects under some exposures. The biphasic (antagonist-to-agonist) behavior also raises uncertainty about dose-dependent effects.

  • Possible adverse tissue effects in vivo: In orchiectomized rats, the highest tested dose (36 mg/kg) was associated with greater atrophy in some androgen/anabolic target tissues, which is a potential safety signal (though the abstract does not detail which tissues or clinical correlates).

  • Quality/labeling and doping concerns: The abstracts emphasize that supplements marketed for anabolic benefits may contain non-approved substances lacking quality control, and that 5α-hydroxy-laxogenin is synthetic despite being marketed as “natural.” This implies risks related to adulteration, mislabeling, and anti-doping rule violations (even if efficacy is unproven).

  • Limitations: The safety and side-effect profile in humans is not established in these abstracts; the in vivo data are from a short (2-week) rat study in a specific model (orchiectomized males).

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings (no genotype-stratified results, no variant-specific effects, and no metabolism/transport gene analyses).

  • What can be inferred (limited): Because 5α-hydroxy-laxogenin interacts with the androgen receptor in vitro, genetic variation in androgen signaling pathways (e.g., AR-related variation) could hypothetically influence response, but this is not tested in the cited studies.

  • Conclusion: No evidence from these abstracts that laxogenin (or 5α-hydroxy-laxogenin) is beneficial or harmful for specific genetic variants.

References

  1. Metabolomics Mechanism and Lignin Response to Laxogenin C, a Natural Regulator of Plants Growth.
    Yuchan Deng, Jiaqi Wang, Annan Zhang, Zhaoju Zhu, Sipei Ren, Cunli Zhang, Qiang Zhang (2022) - International journal of molecular sciences
  2. Androgenic properties of the dietary supplement 5α-hydroxy-laxogenin.
    Carolin Beer, Annekathrin M Keiler (2022) - Archives of toxicology
  3. Effects of the Dietary Supplement 5α-Hydroxy-Laxogenin in the Orchiectomized Rat Model.
    Daniel Derwand, Oliver Zierau, Clemens Alexander Wolf, Gerhard Wolber, Annekathrin Martina Keiler (2025) - Drug testing and analysis


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!